NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| FY 2026 · Annual | ||
| Revenue growth | -13%–-10% | — |
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve EPS of about $0.82 in 2026 | The company expects to earn about $0.82 per share in 2026. | Intact | EPS falls below $0.82 in FY26 | Diluted EPS: $0.84 per share FY2026-Q2; GAAP. Published target: EPS >= $0.82 for fiscal year 2026. Target period is not explicitly aligned with this observation. Source published Aug 12, 20260.84 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: bd19fc6e-5a8e-4df1-a658-b1a78c34c377. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Zero OEM sales to PendoTech in 2026 | A supporting condition in Utah Medical Products, Inc.'s published investment case. The stated target is No OEM sales to PendoTech and no blood pressure kits to China in 2026. | Intact | Any OEM sales to PendoTech or blood pressure kits shipped to China in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain consistent revenue aligned with projections | A primary condition in Utah Medical Products, Inc.'s published investment case. The stated target is Revenue remains at or above $8.72M per quarter. | Broken | Quarterly revenue falls below $8.72M in any quarter | Revenue: $8.529M FY2026-Q2; GAAP. Published target: Revenue remains at or above $8.72M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 12, 20268,529,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: bd19fc6e-5a8e-4df1-a658-b1a78c34c377. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a smaller-cap healthcare business with a recovery-focused thesis, rather than a clear high-growth story. The thesis is marked intact, but confidence is low as replacement sales and the Orion acquisition have yet to offset declining revenue.
The evidence labels UTMD stretched, while also indicating it is cheap versus peers, so the valuation picture is mixed. The expectations gap is 0.21, but the snapshot does not define its scale; it provides limited support for judging what the market already assumes. No valuation fragility gates have fired.
Near term, revenue remains under pressure: nine-month 2026 revenue was lower than the prior-year period, and the full-year sales projection still calls for a decline close to 7%. Orion contributed sales, but third-quarter revenue was still down year over year; litigation costs and pending cases also remain a burden. Recent financial performance is rated strong, though earnings quality is neutral and the near-term miss watch is quiet despite a run of misses.
Over the next few quarters, the key test is whether new biopharma sales, replacement China distributor sales, and Orion can restore revenue growth. A guidance cut or further weakness in jobs could add pressure, while continued earnings strength and higher guidance from healthcare bellwethers could support sector momentum. The snapshot gives no detailed forward financial estimates, and overall confidence is low.
For a 1-to-3-year view, the thesis rests on revenue recovery and control of litigation costs, with current evidence showing only mixed progress. The business setup remains intact, but the valuation signals are mixed and execution uncertainty has risen. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.